PE20240886A1 - Compuestos espirociclicos - Google Patents
Compuestos espirociclicosInfo
- Publication number
- PE20240886A1 PE20240886A1 PE2024000416A PE2024000416A PE20240886A1 PE 20240886 A1 PE20240886 A1 PE 20240886A1 PE 2024000416 A PE2024000416 A PE 2024000416A PE 2024000416 A PE2024000416 A PE 2024000416A PE 20240886 A1 PE20240886 A1 PE 20240886A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- ccl
- independently
- formula
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion se refiere a compuestos espirociclicos de Formula (I) y sales farmaceuticamente aceptables de estos, tambien a procesos y productos intermedios usados para su preparacion, a composiciones farmaceuticas que los contienen y a su uso en el tratamiento de trastornos proliferativos celulares como el cancer de pancreas, colorrectal, de utero, entre otros. En particular, la invencion se refiere a un compuesto de Formula (I), o una sal farmaceuticamente aceptable de este, en donde: el anillo que contiene X e Y es un pirrol y X es NH e Y es CH o X es CH e Y es NH; Z se selecciona entre CH, CF, CCl o, si Q no es N, N; Q se selecciona entre CH, CF, CCl o, si Z no es N, N; m es 0, 1 o 2; n es 0, 1 o 2; p es 1 o 2; R1 se selecciona, en cada caso, independientemente entre F, Cl, CN, entre otros; R2 se selecciona, en cada caso, independientemente entre F, Cl, Me, entre otros; R3 es H, Me, alquilo C1-C3 o fluoroalquilo C1-C3; R4 es H, Me o alquilo C1-C3; R5 es H, Me, alquilo C1-C3, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243267P | 2021-09-13 | 2021-09-13 | |
| PCT/EP2022/075248 WO2023036974A1 (en) | 2021-09-13 | 2022-09-12 | Spirocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240886A1 true PE20240886A1 (es) | 2024-04-24 |
Family
ID=83688613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000416A PE20240886A1 (es) | 2021-09-13 | 2022-09-12 | Compuestos espirociclicos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11939344B2 (es) |
| EP (1) | EP4402143A1 (es) |
| JP (1) | JP7406674B2 (es) |
| KR (1) | KR102624567B1 (es) |
| CN (1) | CN117916241A (es) |
| AR (1) | AR127050A1 (es) |
| AU (1) | AU2022343903A1 (es) |
| CA (1) | CA3230648A1 (es) |
| CL (1) | CL2024000714A1 (es) |
| CO (1) | CO2024002844A2 (es) |
| CR (1) | CR20240160A (es) |
| DO (1) | DOP2024000041A (es) |
| EC (1) | ECSP24028270A (es) |
| IL (1) | IL311254A (es) |
| MX (1) | MX2024003076A (es) |
| PE (1) | PE20240886A1 (es) |
| TW (1) | TW202330538A (es) |
| WO (1) | WO2023036974A1 (es) |
| ZA (1) | ZA202400595B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023327684A1 (en) | 2022-08-15 | 2025-03-20 | Astrazeneca Ab | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| WO2024188999A1 (en) | 2023-03-13 | 2024-09-19 | Astrazeneca Ab | Crystalline form |
| WO2024255863A1 (zh) * | 2023-06-16 | 2024-12-19 | 中山优理生物医药有限公司 | 一种氨基吡啶类化合物、其制备方法、包含其药物组合物及其应用 |
| WO2025059579A1 (en) | 2023-09-15 | 2025-03-20 | Ideaya Biosciences, Inc. | Methods of treating mat2a related diseases |
| WO2025064750A1 (en) | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| WO2025072544A1 (en) | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324483B1 (en) | 1992-10-08 | 1996-09-24 | Warner Lambert Co | Apparatus for multiple simultaneous synthesis |
| US8455477B2 (en) * | 2008-08-05 | 2013-06-04 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
| CN109415336B (zh) | 2016-04-06 | 2023-08-29 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| CA3112591A1 (en) | 2018-10-08 | 2020-04-16 | The Regents Of The University Of Michigan | Small molecule mdm2 protein degraders |
-
2022
- 2022-09-12 CA CA3230648A patent/CA3230648A1/en active Pending
- 2022-09-12 JP JP2023534129A patent/JP7406674B2/ja active Active
- 2022-09-12 CR CR20240160A patent/CR20240160A/es unknown
- 2022-09-12 WO PCT/EP2022/075248 patent/WO2023036974A1/en active Application Filing
- 2022-09-12 IL IL311254A patent/IL311254A/en unknown
- 2022-09-12 AU AU2022343903A patent/AU2022343903A1/en active Pending
- 2022-09-12 CN CN202280059862.4A patent/CN117916241A/zh active Pending
- 2022-09-12 MX MX2024003076A patent/MX2024003076A/es unknown
- 2022-09-12 PE PE2024000416A patent/PE20240886A1/es unknown
- 2022-09-12 KR KR1020237019818A patent/KR102624567B1/ko active Active
- 2022-09-12 EP EP22786303.2A patent/EP4402143A1/en active Pending
- 2022-09-12 TW TW111134225A patent/TW202330538A/zh unknown
- 2022-09-13 AR ARP220102479A patent/AR127050A1/es unknown
-
2023
- 2023-06-15 US US18/335,225 patent/US11939344B2/en active Active
-
2024
- 2024-01-17 ZA ZA2024/00595A patent/ZA202400595B/en unknown
- 2024-02-16 US US18/443,829 patent/US20240270757A1/en active Pending
- 2024-03-06 DO DO2024000041A patent/DOP2024000041A/es unknown
- 2024-03-07 CO CONC2024/0002844A patent/CO2024002844A2/es unknown
- 2024-03-11 CL CL2024000714A patent/CL2024000714A1/es unknown
- 2024-04-11 EC ECSENADI202428270A patent/ECSP24028270A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR127050A1 (es) | 2023-12-13 |
| KR102624567B1 (ko) | 2024-01-11 |
| CN117916241A (zh) | 2024-04-19 |
| KR20230091198A (ko) | 2023-06-22 |
| IL311254A (en) | 2024-05-01 |
| WO2023036974A1 (en) | 2023-03-16 |
| CR20240160A (es) | 2024-05-30 |
| JP2023549418A (ja) | 2023-11-24 |
| ECSP24028270A (es) | 2024-05-31 |
| US20240270757A1 (en) | 2024-08-15 |
| AU2022343903A1 (en) | 2024-05-02 |
| JP7406674B2 (ja) | 2023-12-27 |
| MX2024003076A (es) | 2024-03-27 |
| ZA202400595B (en) | 2024-09-25 |
| US11939344B2 (en) | 2024-03-26 |
| DOP2024000041A (es) | 2024-04-15 |
| TW202330538A (zh) | 2023-08-01 |
| EP4402143A1 (en) | 2024-07-24 |
| CL2024000714A1 (es) | 2024-09-27 |
| US20230357279A1 (en) | 2023-11-09 |
| CA3230648A1 (en) | 2023-03-16 |
| CO2024002844A2 (es) | 2024-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240886A1 (es) | Compuestos espirociclicos | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| AR106755A2 (es) | Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
| AR088919A2 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y uso | |
| AR036106A1 (es) | Compuestos azaindoles inhibidores de quinasa selectivos, composiciones farmaceuticas y el uso de dicha composicion para la fabricacion de un medicamento | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| PE20242071A1 (es) | Compuestos moduladores de diacilglicerol quinasa | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| CO2023000056A2 (es) | Derivados de amidopirimidona | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| PE20240894A1 (es) | Compuesto inductor de la degradacion de plk1 novedoso | |
| MX389378B (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| ECSP088257A (es) | Derivados de amida | |
| AR053835A1 (es) | Tetrahidropiridoazepin - 8 - onas como moduladores del receptor de dopamina d2 y compuestos relacionados para el tratamiento de la esquizofrenia y otros trastornos del snc, composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos. | |
| AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos | |
| AR066150A1 (es) | Compuestos de benzotriazollilfenol sililados sustituidos | |
| AR118641A1 (es) | Compuestos, composiciones y métodos | |
| AR088639A1 (es) | Composicion farmaceutica oftalmica, compuestos antimicrobianos a base de carbolina |